These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 33906872)

  • 21. miR-100-5p confers resistance to ALK tyrosine kinase inhibitors Crizotinib and Lorlatinib in EML4-ALK positive NSCLC.
    Lai Y; Kacal M; Kanony M; Stukan I; Jatta K; Kis L; Norberg E; Vakifahmetoglu-Norberg H; Lewensohn R; Hydbring P; Ekman S
    Biochem Biophys Res Commun; 2019 Apr; 511(2):260-265. PubMed ID: 30791979
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rapid Acquisition of Alectinib Resistance in ALK-Positive Lung Cancer With High Tumor Mutation Burden.
    Makimoto G; Ohashi K; Tomida S; Nishii K; Matsubara T; Kayatani H; Higo H; Ninomiya K; Sato A; Watanabe H; Kano H; Ninomiya T; Kubo T; Rai K; Ichihara E; Hotta K; Tabata M; Toyooka S; Takata M; Maeda Y; Kiura K
    J Thorac Oncol; 2019 Nov; 14(11):2009-2018. PubMed ID: 31374369
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ALK Rearrangement Positive Lung Adenocarcinoma in Pregnancy Treated With Alectinib: A Case Report.
    Gonzalez-Mosquera LF; Rous FA; Rogers A; Smith N; Goyert G; Gadgeel S
    Clin Lung Cancer; 2024 Mar; 25(2):e77-e80. PubMed ID: 38057186
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A novel EML4-ALK BIRC6-ALK double fusion variant in lung adenocarcinoma confers sensitivity to alectinib.
    Zhong JM; Zhang GF; Lin L; Li DY; Liu ZH
    Lung Cancer; 2020 Jul; 145():211-212. PubMed ID: 32409002
    [No Abstract]   [Full Text] [Related]  

  • 25. Left total pneumonectomy performed after alectinib treatment for anaplastic lymphoma kinase-positive lung adenocarcinoma: a case report.
    Wang Z; Shi Y; Zhang P; Chen Y
    Chin Clin Oncol; 2023 Dec; 12(6):70. PubMed ID: 38195077
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cutaneous sarcoid-like drug reaction caused by an anaplastic lymphoma kinase inhibitor.
    Gleue CA; Shah K; Wentworth A; Bridges A
    J Cutan Pathol; 2021 Mar; 48(3):425-428. PubMed ID: 33128468
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Response to treatment with an ALK-TKI in a patient with advanced lung adenocarcinoma with concurrent ALK fusion and high PD-L1 expression: A case report.
    Zhang Y; Fang H; Hong J; Wang X; Wang H; Pan G
    Medicine (Baltimore); 2022 Aug; 101(33):e30094. PubMed ID: 35984185
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Successful Alectinib Treatment for Carcinoma of Unknown Primary with
    Sugiyama K; Izumika A; Iwakoshi A; Nishibori R; Sato M; Shiraishi K; Hattori H; Nishimura R; Kitagawa C
    Curr Oncol; 2021 May; 28(3):1938-1945. PubMed ID: 34064158
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of triple gene fusion ALK-LRRN2, LTBP1-ALK, and HIP1-ALK in advanced lung adenocarcinoma and response to alectinib: A case report.
    Ning S; Shi C; Zhang H; Li J
    Medicine (Baltimore); 2021 Dec; 100(51):e27999. PubMed ID: 34941039
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Receptor ligand-triggered resistance to alectinib and its circumvention by Hsp90 inhibition in EML4-ALK lung cancer cells.
    Tanimoto A; Yamada T; Nanjo S; Takeuchi S; Ebi H; Kita K; Matsumoto K; Yano S
    Oncotarget; 2014 Jul; 5(13):4920-8. PubMed ID: 24952482
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Case report: continued treatment with alectinib is possible for patients with lung adenocarcinoma with drug-induced interstitial lung disease.
    Nitawaki T; Sakata Y; Kawamura K; Ichikado K
    BMC Pulm Med; 2017 Dec; 17(1):173. PubMed ID: 29207989
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ALK-positive lung cancer in a patient with recurrent brain metastases and meningeal dissemination who achieved long-term survival of more than seven years with sequential treatment of five ALK-inhibitors: A case report.
    Yamamoto K; Toyokawa G; Kozuma Y; Shoji F; Yamazaki K; Takeo S
    Thorac Cancer; 2021 Jun; 12(11):1761-1764. PubMed ID: 33939293
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A new human lung adenocarcinoma cell line harboring the EML4-ALK fusion gene.
    Isozaki H; Yasugi M; Takigawa N; Hotta K; Ichihara E; Taniguchi A; Toyooka S; Hashida S; Sendo T; Tanimoto M; Kiura K
    Jpn J Clin Oncol; 2014 Oct; 44(10):963-8. PubMed ID: 25170107
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BRAF V600E mutation as a novel mechanism of acquired resistance to ALK inhibition in ALK-rearranged lung adenocarcinoma: A case report.
    Sui A; Song H; Li Y; Guo L; Wang K; Yuan M; Chen R
    Medicine (Baltimore); 2021 Feb; 100(8):e24917. PubMed ID: 33663128
    [TBL] [Abstract][Full Text] [Related]  

  • 35. EML4-ALK, a potential therapeutic target that responds to alectinib in ovarian cancer.
    Hui B; Zhang J; Shi X; Xing F; Shao YW; Wang Y; Zhang X; Wang S
    Jpn J Clin Oncol; 2020 Dec; 50(12):1470-1474. PubMed ID: 32845005
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Response of a Novel KANK1::ALK Fusion to Alectinib in an Advanced Lung Adenocarcinoma: A Case Report.
    Tang Q; Li T; Ren F; Li X; Cao W; Yu H; Mao F; Cao C; Zu L; Xu S
    J Natl Compr Canc Netw; 2024 Feb; 22(2):. PubMed ID: 38364363
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lung adenocarcinoma with EGFR 19Del and an ALK rearrangement benefits from alectinib instead of an EGFR-TKI: A case report.
    Wang H; Zhu S; Li Z; Qi X; Zhang L; Ke L; Lin Y
    Medicine (Baltimore); 2022 Sep; 101(35):e30316. PubMed ID: 36107507
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
    Solomon BJ; Besse B; Bauer TM; Felip E; Soo RA; Camidge DR; Chiari R; Bearz A; Lin CC; Gadgeel SM; Riely GJ; Tan EH; Seto T; James LP; Clancy JS; Abbattista A; Martini JF; Chen J; Peltz G; Thurm H; Ou SI; Shaw AT
    Lancet Oncol; 2018 Dec; 19(12):1654-1667. PubMed ID: 30413378
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Successful intracranial response of lorlatinib after resistance with alectinib and brigatinib in patients with ALK-positive lung adenocarcinoma: Implications of CNS penetration rate of brigatinib.
    Sato Y; Sato Y; Irie K; Nanjo S; Hara S; Fujiwara S; Tomii K
    Thorac Cancer; 2024 Aug; 15(23):1772-1775. PubMed ID: 38924375
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Successful oral desensitization against skin rash induced by alectinib in a patient with anaplastic lymphoma kinase-positive lung adenocarcinoma: A case report.
    Shirasawa M; Kubotaa M; Harada S; Niwa H; Kusuhara S; Kasajima M; Hiyoshi Y; Ishihara M; Igawa S; Masuda N
    Lung Cancer; 2016 Sep; 99():66-8. PubMed ID: 27565916
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.